BioCryst Pharmaceuticals, Inc. BCRX shares are trading higher Monday. The company provided preliminary, unaudited net revenue figures for Orladeyo (berotralstat) last Friday.
What To Know:
BioCryst announced its preliminary, unaudited Orladeyo net revenue of $89.9 million for the fourth quarter and full year 2023 net revenue of $325 million last Friday.
The company also said that it expects full year 2024 global net Orladeyo revenue to be between $380 million and $400 million.
"After three years on the market, Orladeyo continues on a steady growth trajectory to achieve $1 billion at peak. This commercial success, alongside our proven discovery platform that is producing additional first-in-class or best-in-class molecules, uniquely positions BioCryst to achieve financial independence from the capital markets and accelerate our path to profitability," said Jon Stonehouse, CEO of BioCryst.
Needham analyst Serge Belanger reiterated BioCryst Pharmaceuticals with a Buy and maintained $12 price target on Monday. Needham highlighted the company's desire to seek to partner its BCX10013 program and potential profitability by 2025 without seeking additional capital.
Related News: Why Aclarion Stock Is Trading Higher Today
BCRX Price Action: According to Benzinga Pro, BioCryst Pharmaceuticals shares are up 19% at $7.27 at the time of publication.
Image: Steve Buissinne from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
